Last reviewed · How we verify
JSKN016 Q2W
At a glance
| Generic name | JSKN016 Q2W |
|---|---|
| Sponsor | Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors (PHASE1)
- JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JSKN016 Q2W CI brief — competitive landscape report
- JSKN016 Q2W updates RSS · CI watch RSS
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd portfolio CI